(c) 2024 PillSync.com

abiraterone 250 mg

1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with • Metastatic castration-resistant prostate cancer (CRPC) • Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with • metastatic castration-resistant prostate cancer (CRPC). ( 1 ) • metastatic high-risk castration-sensitive prostate cancer (CSPC). ( 1 )

mylan pharmaceuticals inc.


3 years ago OVAL WHITE M AB250 abiraterone 250 mg

OVAL WHITE M AB250

16 HOW SUPPLIED/STORAGE AND HANDLING

ABIRATERONE ACETATE Tablets, USP are available containing 250 mg or 500 mg of

ABIRATERONE ACETATE, USP. 500 mg film-coated tablets: The 500 mg tablets are white, film-coated, oval, unscored tablets debossed with M on one side of the tablet and AB500 on the other side. They are available as follows: NDC 0378-6921-91 bottles of 60 tablets 250 mg uncoated tablets: The 250 mg tablets are white to off-white, oval, unscored tablets debossed with M on one side of the tablet and AB250 on the other side. They are available as follows: NDC 0378-6920-78 bottles of 120 tablets Storage and Handling: Store at 20° to 25°C (68° to 77°F); excursions permitted in the range from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Keep out of reach of children. Based on its mechanism of action,

ABIRATERONE ACETATE tablets may harm a developing fetus. Women who are pregnant or women who may be pregnant should not handle

ABIRATERONE ACETATE 250 mg uncoated tablets or other

ABIRATERONE ACETATE tablets if broken, crushed, or damaged without protection, e.g., gloves [see Use in Specific Populations (8.1) ] .


More pills like OVAL M AB250

Related Pills

abiraterone 500 mg

mylan pharmaceuticals inc.

abiraterone acetate 250 MG Oral Tablet

Mylan Pharmaceuticals Inc.












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site